A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors with a KRAS G12C Mutation

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506311-18-00

Acronym

GO42144

Enrollment

156

Registered

2024-06-19

Start date

2021-06-29

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic solid tumors with KRAS G12C mutation

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Hungary, Italy, Netherlands, Norway, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026